Spanish Prime Minister Pedro Sanchez gave the idea endorsed by US President Joe Biden this week a guarded welcome, but he immediately added, "We believe it is insufficient. It should be more ambitious."
While the US has kept a tight lid on exports of American-made vaccines so it can inoculate its own population first, the EU has become the world's leading provider, allowing about as many doses to go outside the 27-nation bloc as are kept for its 446 million inhabitants.
Many EU nations, however, have demanded a stop to vaccine nationalism and export bans.
Von der Leyen said that any patent waiver will not bring a single dose of vaccine in the short and medium term."
Macron said it was more important for Biden to work on exports.
"The Anglo-Saxons block many of these ingredients" needed to make vaccines, the French leader said, referring to Washington and London.
"Today, 100% of vaccines produced in the United States of America are for the American market."
European Commission President Ursula von der Leyen said this week that the EU had distributed about 200 million doses within the bloc while about the same amount had been exported abroad.
"Around 50 per cent of what is being produced in Europe is exported to almost 90 countries," von der Leyen said, and called on Biden and other vaccine producing regions or nations to step up their effort.
"We are the most generous in the world of developed nations. Europe should be proud of itself, Macron said.
The EU is trying to regain the diplomatic initiative on vaccines after Biden put it on the back foot with his surprising endorsement of lifting patent protections on COVID-19 vaccines, seeking to solve the problem of getting shots into the arms of people in poorer countries.
EU leaders said they were ready to discuss the US backing for proposals first submitted to the World Trade Organisation by India and South Africa, but they said many other initiatives would be more effective at this point, ranging from ramping up production capacity to distributing raw materials.
So far, they insisted, the issue of waiving patents is not a big problem.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.